Gilead Sciences Total Assets 2010-2022 | GILD

Gilead Sciences total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Gilead Sciences total assets for the quarter ending September 30, 2022 were $62.557B, a 6.77% decline year-over-year.
  • Gilead Sciences total assets for 2021 were $67.952B, a 0.67% decline from 2020.
  • Gilead Sciences total assets for 2020 were $68.407B, a 11% increase from 2019.
  • Gilead Sciences total assets for 2019 were $61.627B, a 3.22% decline from 2018.
Gilead Sciences Annual Total Assets
(Millions of US $)
2021 $67,952
2020 $68,407
2019 $61,627
2018 $63,675
2017 $70,283
2016 $56,977
2015 $51,716
2014 $34,664
2013 $22,579
2012 $21,240
2011 $17,303
2010 $11,593
2009 $9,699
Gilead Sciences Quarterly Total Assets
(Millions of US $)
2022-09-30 $62,557
2022-06-30 $62,870
2022-03-31 $63,080
2021-12-31 $67,952
2021-09-30 $67,098
2021-06-30 $67,984
2021-03-31 $67,492
2020-12-31 $68,407
2020-09-30 $60,878
2020-06-30 $55,934
2020-03-31 $59,741
2019-12-31 $61,627
2019-09-30 $59,146
2019-06-30 $63,210
2019-03-31 $62,837
2018-12-31 $63,675
2018-09-30 $64,305
2018-06-30 $65,355
2018-03-31 $65,381
2017-12-31 $70,283
2017-09-30 $64,662
2017-06-30 $60,263
2017-03-31 $57,701
2016-12-31 $56,977
2016-09-30 $56,609
2016-06-30 $49,980
2016-03-31 $47,765
2015-12-31 $51,716
2015-09-30 $50,637
2015-06-30 $39,167
2015-03-31 $38,321
2014-12-31 $34,664
2014-09-30 $28,844
2014-06-30 $31,206
2014-03-31 $28,078
2013-12-31 $22,579
2013-09-30 $22,468
2013-06-30 $22,624
2013-03-31 $22,212
2012-12-31 $21,240
2012-09-30 $20,964
2012-06-30 $20,502
2012-03-31 $19,950
2011-12-31 $17,303
2011-09-30 $12,640
2011-06-30 $12,694
2011-03-31 $12,987
2010-12-31 $11,593
2010-09-30 $11,456
2010-06-30 $10,497
2010-03-31 $10,696
2009-12-31 $9,699
2009-09-30 $8,937
2009-06-30 $8,387
2009-03-31 $7,520
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $104.541B $27.305B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00